Innovent Biopharmaceutical Transformation
Robust Pipeline Across Novel Therapeutics - Oncology
6 approved, 1 NDA, 4 in pivotal trials and 14 assets in clinical stage
Launched
Lilly
Products
Target (s)
Modality
Therapeutic Area
Commercial Rights
TYVYT (sintilimab injection)
PD-1
BYVASDA (bevacizumab injection)
VEGF-A
HALPRYZAⓇ (rituximab injection)
Pemazyre (Pemigatinib)
CD20
FGFR1/2/3
Monoclonal antibody
Monoclonal antibody
Monoclonal antibody
Oncology
Worldwide
Oncology
Worldwide
Pre-clinical
IND Approved
Status
Phase 1
Phase 2
NDA
Pivotal Phase
2/ Phase 3
Approved: 1L nsqNSCLC, 1L sqNSCLC, 1L HCC, CHL; NDA submitted: 1L GC, 1L ESCC, EGFRM NSCLC after EGFR TKI
Approved: NSCLC, MCRC, HCC, rGBM, r/r CC, OC
Oncology
Worldwide
Approved: nHL, CLL and WG
Small molecule
Oncology
Olverembatinib (BCR/ABL TKI)
BCR-ABL/KIT
Small molecule
Oncology
Mainland China, HK, Taiwan, Macau
Mainland China, HK, Taiwan, Macau
Approved: 2L CCA
Approved: 2L TKI-resistant CML
Cyramza (ramucirumab)
VEGFR-2
Monoclonal antibody
Oncology
Retsevmo (selpercatinib)
RET
Small molecule
Oncology
Mainland China,
Mainland China
Approved : 2L GC, NDA submitted: 2L HCC
IBI-310
CTLA-4
Monoclonal antibody
Oncology
Worldwide
IBI-376 (Parsaclisib)
PI3K8
Small molecule
Oncology
Mainland China, HK, Taiwan, Macau
IBI-326
BCMA CAR-T
Cell therapy
Oncology
Worldwide
IBI-344 (Taletrectinib)
ROS1/NTRK
Small molecule
Oncology
Mainland China, HK, Taiwan, Macau
IBI-188
CD47
Monoclonal antibody
Oncology
Worldwide
IBI-110
LAG-3
Monoclonal antibody
Oncology
Worldwide
IBI-322
PD-L1/CD47
Bispecific antibody
Oncology
Worldwide
IBI-351
KRAS
Small molecule
Oncology
Worldwide
RETM NSCLC/TC
2L Cervical cancer
1 HCC
r/r FL; MZL
Myelofibrosis (Incyte's global Phase 3)
r/r multiple myeloma
ROS1+ NSCLC (1L + 2L)
NTRK+ Solid tumors
MDS (China)
MDS (US)
Phase 1b and Phase 2 for multiple cancer types
Advanced malignancies
Advanced malignancies (US)
KRAS+ NSCLC/CRC
NSCLC
IBI-939
TIGIT
Monoclonal antibody
Oncology
Worldwide
IND approved (US)
IBI-321
PD-1/TIGIT
Bispecific antibody
Oncology
Mainland China, HK, Macau
Advanced malignancies
IBI-319
PD-1/4-1BB
Bispecific antibody
Oncology
Mainland China, HK, Macau
IBI-323
LAG-3/PD-L1
Bispecific antibody
Oncology
Worldwide
Advanced malignancies
Advanced malignancies
IBI-315
PD-1/HER2
Bispecific antibody
Oncology
Worldwide
Advanced malignancies
IBI-360
CLDN18.2
Monoclonal antibody
Oncology
Worldwide
Advanced malignancies
IBI-389
IBI-346
CLDN18.2/CD3
CLDN18.2 Modular CAR-T
Bispecific antibody
Oncology
Worldwide
Advanced malignancies
Cell therapy
Oncology
IBI-325
CD73
Monoclonal antibody
Oncology
IBI-397
SIRPa
Monoclonal antibody
Oncology
Worldwide
Worldwide
Mainland China, HK, Taiwan, Macau
Advanced malignancies
Advanced malignancies
Advanced malignancies
Listed drugs
Biologics
Coherus.
Lilly
(Incyte
旦
Lilly
Lilly
Incyte
AnHeart
驹方医药
GENFLEET
Lilly
Lilly
Hanmi
Small molecules
Clinical progress in the U.S.
Robust oncology pipeline with 25 clinical stage assets, covering monoclonal antibodies, bispecific antibodies, CAR-T and small
Innovent
molecules
Confidential
Copyright©2022 Innovent
26
26View entire presentation